Results 121 to 130 of about 2,234,624 (258)

MRP2 as a Targetable Oxaliplatin Resistance Factor in Gastrointestinal Cancer

open access: yes, 2018
Despite the severe adverse effects, toxicity and limited efficacy due to the development of multidrug resistance (MDR), chemotherapy is still the treatment of choice for most of the cancer patients.
Biswas, Riya
core   +1 more source

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue   +6 more
wiley   +1 more source

Fertility counseling and preservation considerations in patients with gynecologic and non‐gynecologic BRCA and Lynch‐associated malignancies

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Lynch syndrome and BRCA‐mutation associated malignancies are fortunately rare. Affected patients have an increased risk of cancer diagnosis at a young age, often significantly overlapping with their reproductive years. In helping these patients, oncologists must navigate the following areas of care: cancer prevention, impact of cancer ...
Anna Weimer   +20 more
wiley   +1 more source

Multi‐omics–driven precision medicine

open access: yesiMeta, EarlyView.
Multi‐omics‐driven precision medicine (MODPM) provides a multiscale, continuously learnable framework that integrates genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and clinical data. Powered by artificial intelligence and foundation models, MODPM enables cross‐modal representation learning, contextual modeling ...
Huibo Li   +20 more
wiley   +1 more source

Liquid biopsy across cancers: Integrating circulating biomarkers, tumor biology, artificial intelligence, and clinical translation

open access: yesInterdisciplinary Medicine, EarlyView.
Liquid biopsy uses non‐invasive sampling of blood or body fluids to isolate circulating analytes, including circulating tumor DNA, circulating tumor cells, extracellular vesicles, and RNA. These are analyzed using next‐generation sequencing, qPCR, and proteomics to inform cancer detection, monitoring, and characterization. Figure created with BioRender.
Jaswinder Singh   +2 more
wiley   +1 more source

New Hydrazone Derivatives Featuring Isatin and Piperazine Moieties: Synthesis, Cytotoxicity Evaluation, and Molecular Modeling Studies

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT In this study, ten novel compounds (IPH1–IPH10) were designed by integrating three pharmacophores (isatin, piperazine, and hydrazone) commonly found in the molecular structures of anticancer agents. The target molecules were obtained by the reaction of in‐house prepared 4‐(4‐(pyridin/pyrimidin‐2‐yl)piperazin‐1‐yl)benzohydrazide with various ...
Semiha Köprü   +3 more
wiley   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

open access: yesMed Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang   +9 more
wiley   +1 more source

DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer

open access: yesOncogenesis
Oxaliplatin is effective against colorectal cancer (CRC), but resistance hampers treatment. We found upregulated Dickkopf-1 (DKK1, a secreted protein) in oxaliplatin-resistant (OR) CRC cell lines and DKK1 levels increased by more than 2-fold in ...
Chi-Che Hsieh   +6 more
doaj   +1 more source

Oxaliplatin in Cisplatin-Resistant Cancer

open access: yes, 2007
Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with ...
STORDAL, BRITTA KRISTINA
core  

Home - About - Disclaimer - Privacy